Access to medical products is a complex global challenge at the interface between health, economics, politics and development. This one-day symposium organised in collaboration with the Swiss Federal Institute of Intellectual Property and the Federal Office of Public Health will focus on a sub-set of access to medicines challenges, using Hepatitis C virus (HCV) as an extended case study to facilitate discussions and novel thinking.
The purpose of the event is to spur fresh thinking on how to achieve innovation and global access to medicines, following up on the Swiss Federal Institute of Intellectual Property (IPI) Stakeholder Discussions in February 2018 in Bern. The case study approach is intended to advance the debate beyond generalities by focusing on a suite of specific strategies in relation to one class of health technologies, which may be an illustrative example of many new medicines to come.